WW revenue falls 8.3% to $162.3M; EPS drops 90% as Clinical pivot offsets Behavioral decline

Filed August 5, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 11, 2025 · ~1 min read

Key Changes

• high

  Total revenue declined 8.3% to $162.3M, driven by falling Behavioral subscriptions, partially offset by Clinical growth from Med+ and lower-priced GLP-1 options.

  MD&A: Revenue verify on EDGAR →
• high

  Diluted EPS fell 90.4% to $1.41, reflecting lower operating income and higher costs, despite a $4.6M gain on debt extinguishment.

  MD&A: Results verify on EDGAR →
• high

  Behavioral reporting unit and trade name intangible flagged as at risk for impairment, with fair value cushion below 10%.

  Notes: Impairment verify on EDGAR →